These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34422625)

  • 1. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
    Wen Q; Yang Z; Dai H; Feng A; Li Q
    Front Oncol; 2021; 11():620246. PubMed ID: 34422625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
    Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
    EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
    Wen Q; Yang Z; Zhu J; Qiu Q; Dai H; Feng A; Xing L
    Onco Targets Ther; 2020; 13():12003-12013. PubMed ID: 33244242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
    Wang J; Wang J; Huang X; Zhou Y; Qi J; Sun X; Nie J; Hu Z; Wang S; Hong B; Wang H
    BMC Med Imaging; 2024 Feb; 24(1):45. PubMed ID: 38360550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
    Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
    J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by
    Li J; Ge S; Sang S; Hu C; Deng S
    Front Oncol; 2021; 11():789014. PubMed ID: 34976829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing a predictive model for tumor mutation burden status based on CT radiomics and clinical features of non-small cell lung cancer patients.
    Yang J; Shi W; Yang Z; Yu H; Wang M; Wei Y; Wen J; Zheng W; Zhang P; Zhao W; Chen L
    Transl Lung Cancer Res; 2023 Apr; 12(4):808-823. PubMed ID: 37197623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
    Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
    Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep learning radiomics model based on PET/CT predicts PD-L1 expression in non-small cell lung cancer.
    Li B; Su J; Liu K; Hu C
    Eur J Radiol Open; 2024 Jun; 12():100549. PubMed ID: 38304572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparameter spectral CT-based radiomics in predicting the expression of programmed death ligand 1 in non-small-cell lung cancer.
    Zheng XX; Ma YQ; Cui YQ; Dong SS; Chang FX; Zhu DL; Huang G
    Clin Radiol; 2024 Apr; 79(4):e511-e523. PubMed ID: 38307814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer.
    Xu T; Liu X; Chen Y; Wang S; Jiang C; Gong J
    BMC Med Imaging; 2024 Jul; 24(1):196. PubMed ID: 39085788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
    Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X
    Front Oncol; 2021; 11():769272. PubMed ID: 34868999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study.
    Liu Z; Yao Y; Zhao M; Zhao Q; Xue J; Huang Y; Qin S
    Acad Radiol; 2024 Jul; ():. PubMed ID: 39084935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral and Peritumoral Radiomics Based on Preoperative MRI for Evaluation of Programmed Cell Death Ligand-1 Expression in Breast Cancer.
    Wu Z; Lin Q; Wang H; Chen J; Wang G; Fu G; Li L; Bian T
    J Magn Reson Imaging; 2024 Aug; 60(2):588-599. PubMed ID: 37916918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma.
    Gong XQ; Liu N; Tao YY; Li L; Li ZM; Yang L; Zhang XM
    Sci Rep; 2023 May; 13(1):7710. PubMed ID: 37173350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of computed tomography radiomics combined with inflammation indices in predicting the efficacy of immunotherapy in patients with locally advanced and metastatic non-small cell lung cancer.
    Shao H; Zhu J; Shi L; Yao J; Wang Y; Ma C; Swierniak A; Ni B
    J Thorac Dis; 2024 May; 16(5):3213-3227. PubMed ID: 38883654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer.
    Qiu Q; Xing L; Wang Y; Feng A; Wen Q
    Front Immunol; 2022; 13():870842. PubMed ID: 35558076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CT-based radiomics signature for preoperative discrimination between high and low expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
    Zheng YM; Zhan JF; Yuan MG; Hou F; Jiang G; Wu ZJ; Dong C
    Eur J Radiol; 2022 Jan; 146():110093. PubMed ID: 34890937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.